• Generic Name: latanoprostene bunod ophthalmic solution
  • Brand Name: Vyzulta
Last updated on MDtodate: 10/8/2022


The following adverse reactions are described elsewhere in the labeling:

  • Pigmentation
  • Eyelash Changes
  • Intraocular Inflammation
  • Macular Edema
  • Bacterial Keratitis
  • Use with Contact Lens

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

VYZULTA was evaluated in 811 patients in 2 controlled clinical trials of up to 12 months duration. The most common ocular adverse reactions observed in patients treated with latanoprostene bunod were: conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%). Approximately 0.6% of patients discontinued therapy due to ocular adverse reactions including ocular hyperemia, conjunctival irritation, eye irritation, eye pain, conjunctival edema, vision blurred, punctate keratitis and foreign body sensation.